Source: Skye Bioscience, Inc. 4/10/2024
Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the
"Company"), a clinical-stage biotechnology company focused on the
discovery, development and commercialization of novel classes of
therapeutic drugs that modulate the endocannabinoid system, with an
emphasis on obesity and ocular indications, announced today that the
Company has received approval to list its common stock on the Nasdaq
Global Market® stock exchange ("Nasdaq"). The Company's common stock is
expected to commence trading on Nasdaq at the market open on Thursday,
April 11th, 2024, under the ticker symbol "SKYE". The Company's common
stock will no longer trade on the over-the-counter securities market.
"Skye’s approval to trade on The Nasdaq Global Market reflects the culmination of important accomplishments in the advancement of both of our Phase 2 clinical programs, financial position, and shareholder base, which are a reflection of Skye's commitment to corporate governance and execution of its business strategy," said Kaitlyn Arsenault, Chief Financial Officer. "We believe that uplisting to the Nasdaq Global Market will enhance our visibility in the marketplace, expose us to a larger audience of investors, elevate our profile in the investment community, increase trading liquidity and ultimately enhance long-term shareholder value."
"This listing to the Nasdaq Global Market is a validation of Skye and its recent performance," said Punit Dhillon, Chief Executive Officer and Chairman. "We expect top-line clinical data from our Phase 2 glaucoma study this quarter and our fully-funded Phase 2 clinical trial for our obesity-focused peripheral CB1 inhibitor to be launched in Q3 2024."
About Skye Bioscience
No comments:
Post a Comment